WINNIPEG, MB, Nov. 15, 2024 /CNW/ - IGM Financial Inc. (IGM) (TSX: IGM) today announced it has been recognized as one of Canada's Top 100 Employers by Mediacorp Canada Inc (Mediacorp). This is the ...

This is the fourth year that Mediacorp has recognized the IGM family of companies in this ranking. IGM logo (CNW Group/IGM Financial Inc.) Compiled and published annually, the ranking recognizes the ...

BMO Capital initiated coverage of IGM Biosciences (IGMS) with an Outperform rating and $21 price target IGM is a clinical-stage biotechnology ...

Receive News & Ratings for IGM Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Financial and related companies ...

On average, equities analysts expect that IGM Biosciences will post -3.33 EPS for the current fiscal year. In other news, CEO Fred Schwarzer sold 3,946 shares of IGM Biosciences stock in a ...

Including IPC, IGM reported total net outflows of $291 million and investment fund net redemptions of $636 million in November 2023. Assets Under Management and Advisement (AUM&A) represents the ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

IGM Biosciences has pivoted from cancer therapeutics to autoimmune diseases despite setbacks, showing a 25% stock increase since last October. Click for more on IGMS.

IGM Biosciences, Inc.'s (NASDAQ:IGMS) Chief Financial Officer, Tahir Misbah, recently sold shares of the company stock, according to the latest SEC filings. The ...

Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter ...